We in-licensed Genecast IVD - MammaPrint from Agendia, our breast cancer testing reagent kit, to be used in the targeted RNA sequencing, NGS-based diagnostic testing of early-stage invasive breast cancer, indicates the prognostic profile for the risk of breast cancer recurrence, and assists in postoperative chemotherapy decision-making. According to Frost & Sullivan, MammaPrint is the first NGS-based breast cancer recurrence assay offered in China. MammaPrint's clinical validity and utility are supported by over 20 years of clinical validation, 200 research collaborations and hundreds of publications.